These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 28669027)

  • 1. The impact of structural biology in medicine illustrated with four case studies.
    Hu T; Sprague ER; Fodor M; Stams T; Clark KL; Cowan-Jacob SW
    J Mol Med (Berl); 2018 Jan; 96(1):9-19. PubMed ID: 28669027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural biology contributions to tyrosine kinase drug discovery.
    Cowan-Jacob SW; Möbitz H; Fabbro D
    Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Progress in the fragment-based drug discovery].
    Ren J; Li J; Shi F; Wang X; He JH; Xu YC; Zhang NX; Xiong B; Shen JK
    Yao Xue Xue Bao; 2013 Jan; 48(1):14-24. PubMed ID: 23600136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and Future Challenges in GPCR Drug Discovery.
    Topiol S
    Methods Mol Biol; 2018; 1705():1-21. PubMed ID: 29188556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of natural products in modern drug development.
    Dev S
    Indian J Exp Biol; 2010 Mar; 48(3):191-8. PubMed ID: 21046971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of systems biology in cancer immunotherapy: from target discovery to biomarkers of clinical outcome.
    Guhathakurta D; Sheikh NA; Meagher TC; Letarte S; Trager JB
    Expert Rev Clin Pharmacol; 2013 Jul; 6(4):387-401. PubMed ID: 23927667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. X-ray crystallography over the past decade for novel drug discovery - where are we heading next?
    Zheng H; Handing KB; Zimmerman MD; Shabalin IG; Almo SC; Minor W
    Expert Opin Drug Discov; 2015; 10(9):975-89. PubMed ID: 26177814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth factor receptors: structure, mechanism, and drug discovery.
    McInnes C; Sykes BD
    Biopolymers; 1997; 43(5):339-66. PubMed ID: 9566117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights from structural analysis of cFMS/inhibitor complexes: common interactions via three structurally dissimilar scaffolds.
    DesJarlais RL
    Curr Top Med Chem; 2012; 12(11):1271-81. PubMed ID: 22571789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of computational structure-based methods on drug discovery.
    Reynolds CH
    Curr Pharm Des; 2014; 20(20):3380-6. PubMed ID: 23947642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural products drug discovery research in India: status and appraisal.
    Bhutani KK; Gohil VM
    Indian J Exp Biol; 2010 Mar; 48(3):199-207. PubMed ID: 21046972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of experimental and computational structural approaches in 7TM drug discovery.
    Topiol S; Sabio M
    Expert Opin Drug Discov; 2015 Oct; 10(10):1071-84. PubMed ID: 26211671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
    Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
    Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational approaches to natural-product-based drug design.
    Haustedt LO; Mang C; Siems K; Schiewe H
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):445-62. PubMed ID: 16889228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
    Schoepfer J; Jahnke W; Berellini G; Buonamici S; Cotesta S; Cowan-Jacob SW; Dodd S; Drueckes P; Fabbro D; Gabriel T; Groell JM; Grotzfeld RM; Hassan AQ; Henry C; Iyer V; Jones D; Lombardo F; Loo A; Manley PW; Pellé X; Rummel G; Salem B; Warmuth M; Wylie AA; Zoller T; Marzinzik AL; Furet P
    J Med Chem; 2018 Sep; 61(18):8120-8135. PubMed ID: 30137981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rectifying cancer drug discovery through network pharmacology.
    Azmi AS; Mohammad RM
    Future Med Chem; 2014 Apr; 6(5):529-39. PubMed ID: 24649956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications of In-Cell NMR in Structural Biology and Drug Discovery.
    Kang C
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30609728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.